Inebilizumab for children with NMOSD who had recent relapses
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 2 to under 18 years old, and weighs at least 15 kg
- Blood test is positive for AQP4-IgG, and a doctor has diagnosed NMOSD
- Your child had NMOSD relapses recently (one in the last year, or two in the past two years)
- Your child can safely do study checkups and procedures, including MRI if needed
- Your child has not had certain immune treatments or vaccines in the listed time windows (often weeks to months)
- Screening tests show no major liver, kidney, blood, or infection problems that could raise risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
This trial studies ofatumumab to reduce disease activity in adults with AQP4-IgG positive NMOSD who have had recent relapses. It may help lower the chance of new attacks and help prevent worsening disability over time.
This trial tests a new drug called inectolizumab combined with steroids for people having their first attack of NMOSD, a rare autoimmune disease that can cause vision loss and paralysis. The goal is to see if this combination is safe and helps reduce symptoms.
This trial is for people with NMOSD who have recently had an attack. It compares two ways of slowly reducing steroid treatment while also receiving an experimental drug called inebilizumab, to see which approach helps prevent future attacks better.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
Hear when a new Neuromyelitis Optica Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.